Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Ajai ChariDan T VoglMaria GavriatopoulouAjay K NookaAndrew J YeeCarol A HuffPhilippe MoreauDavid DingliCraig ColeSagar LonialMeletios DimopoulosA Keith StewartJoshua RichterRavi VijSascha TuchmanMarc S RaabKatja C WeiselMichel DelforgeRobert F CornellDavid KaminetzkyJames E HoffmanLuciano José Megale CostaTerri L ParkerMoshe LevyMartin SchrederNathalie MeulemanLaurent FrenzelMohamad MohtySylvain ChoquetGary SchillerRaymond L ComenzoMonika EngelhardtThomas IllmerPhilip VlummensChantal DoyenThierry FaconLionel KarlinAurore PerrotKlaus PodarMichael G KauffmanSharon ShachamLingling LiShijie TangCarla PicklesimerJean-Richard Saint-MartinMarsha CrochiereHua ChangSamir ParekhYosef LandesmanJatin ShahPaul G RichardsonSundar JagannathPublished in: The New England journal of medicine (2019)
Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).